Posted June 27, 2012
An article in JAMA (June 6, 2012, Vol. 307, No. 21, page 2247) states, “For years, nonsteroidal anti-inflammatory drugs that target the…Cox-2 enzyme have been linked to increased cardiovascular risks. New research indicates that these elevated risks occur because COX-2 inhibitors suppress prostacyclin—a vasodilator and platelet inhibitor with heart protecting properties.” This ‘new’ research has come much too late for the 50,000 who died and over 100,000 patients who suffered a stroke or a heart attack directly related to the use of a COX-2 inhibitor such as Vioxx or Celebrex. Read more.